Clinical Hold

Clinical Hold - Axcellant

Clinical Hold

  1. lut 28, 2025

What Does 'Clinical Hold’ Mean?

A clinical hold is a regulatory action taken by the U.S. Food and Drug Administration (FDA) to temporarily suspend or delay a clinical trial. This action is typically implemented when the FDA identifies potential safety concerns or other issues that require further investigation or resolution before the trial can proceed.

During a clinical hold, no new participants can be enrolled in the study, and existing participants must not receive the investigational product. The sponsor of the clinical trial must address the FDA’s concerns and provide additional information or make necessary changes before the hold can be lifted and the trial allowed to continue.

Why Is the 'Clinical Hold’ Important in Clinical Research?

The term 'clinical hold’ is crucial in clinical research as it serves as a critical safety mechanism to protect study participants and ensure the integrity of clinical trials. It allows regulatory bodies to intervene when potential risks or concerns arise, ensuring that patient safety remains the top priority throughout the research process.

Understanding clinical holds is essential for sponsors, investigators, and other stakeholders in clinical research to navigate regulatory requirements effectively. It emphasizes the importance of rigorous study design, thorough safety monitoring, and prompt addressing of any issues raised by regulatory authorities to maintain the progress and validity of clinical trials.

Good Practices and Procedures

  1. Establish a rapid response team dedicated to addressing clinical holds, including regulatory affairs specialists, medical experts, and data analysts.
  2. Implement a proactive risk assessment protocol to identify potential issues that could lead to a clinical hold before they arise.
  3. Develop a comprehensive communication plan to keep all stakeholders informed and aligned during a clinical hold situation.
  4. Create a detailed remediation tracking system to monitor progress on addressing FDA concerns and ensure timely resolution.
  5. Conduct regular mock clinical hold scenarios to train staff and test the organization’s readiness to respond effectively.

Related Terms

Read more

How clinical trials can become a strategic asset for biotech startups

Clinical trials are often seen as a regulatory necessity, but for biotech and medtech startups, they can be much more.…

Advancing PET Innovation at SNMMI 2025

Axcellant participated in SNMMI’s 2025 Annual Meeting in New Orleans, where nearly 8,000 professionals in nuclear medicine and molecular imaging gathered…

Insights from Turku PET Symposium 2025

Axcellant participated in the PET Symposium 2025, held in Turku, marking 50 years of PET radiochemistry at the Turku PET…